KENILWORTH, N.J., Dec. 22 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced the appointment by the Board of Directors of its Indian affiliate, Fulford (India) Limited, of K.G. Ananthakrishnan as chief operating officer of Fulford. Ananthakrishnan assumed the role of chief operating officer on December 8, 2006, as a transition to the position of president and managing director of Fulford. This transition will, in view of applicable Indian regulations, take effect only on the completion of the currently pending public offer for acquisition of shares in Fulford by Schering-Plough's wholly owned indirect subsidiary, Dashtag. Ananthakrishnan will report directly to the Board of Directors of Fulford. He replaces K.D. Shah, who is leaving the company on December 31, 2006 after 29 years of service.

Ananthakrishnan, 49, and a native of India, brings an extensive background in the region's pharmaceutical industry to his new role. Since 2003 he has served on the senior management team of Pfizer India. He also was a member of the Board of Directors of Capsugel Healthcare Ltd., a Pfizer affiliated company. He helped achieve significant sales growth, profitability and global alignment of the product portfolio. He was instrumental in the successful launch of six global brands during 2005 and 2006. Prior to Pfizer, Ananthakrishnan served in various senior positions with the former Pharmacia Corporation and Novartis.

"As a senior member of our leadership team, Ananthakrishnan will help bring energy and enthusiasm to the Fulford operation," said Dr. Venkat Sohoni, Chairman of the Board of Fulford. "The team is totally committed to growth and looks forward to the business opportunities ahead."

Ananthakrishnan earned a Bachelor of Science degree and Master of Arts degree in marketing management from Jamnalal Bajaj Institute of Management Studies, Bombay University.

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 32,000 people around the world.

The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SOURCE Schering-Plough Corporation